ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1972

Creatine Kinase in the United States Population: Impact of Demographics, Comorbidities and Body Composition on the Normal Range

Neilia-Kay McGill, Joshua F. Baker and Michael D. George, Rheumatology, University of Pennsylvania, Philadelphia, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Creatinine kinase, laboratory tests, myopathy and race/ethnicity

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Healthcare Disparities in Rheumatology

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The accurate interpretation of creatine kinase (CK) values is critical as this laboratory measure guides the workup of suspected myopathies. Incidentally discovered CK elevation is a common reason for rheumatology referral. This study comprehensively evaluated clinical factors associated with CK levels among a nationally representative sample and determined the distribution of CK levels in race-ethnicity subgroups.

Methods: Data was analyzed from the cross-sectional National Health and Nutrition Examination Survey (NHANES) 2011-2014, which interviews and examines a representative sample of the U.S. population. Included subjects were non-pregnant adults ≥ 20 years old. Race-ethnicity was based on self-report. In analyses stratified by sex, linear and logistic regression was used to identified clinical variables associated with CK levels and the likelihood of an individual being outside of sex-specific reference ranges. To assess the role of muscle mass on race-ethnicity differences in CK, linear models were adjusted for body mass index (BMI), arm circumference, and waist circumference. In order to inform the appropriate upper limit of normal reference range, 95th percentiles of CK in sex/race-ethnicity subgroups were calculated, excluding patients with strenuous exercise in the past 3 days.

Results: A total of 10,096 subjects were included: 4119 non-Hispanic white, 2256 non-Hispanic black, 2159 Hispanic and 1270 Asian subjects. In linear and logistic regression, race-ethnicity was most strongly associated with CK among men and women. Compared to white subjects, CK was more likely to be abnormal in black men (OR 8.39, 95% CI 6.11 to 11.52) and in black women (OR 5.08, 95% CI 3.65 to 7.08). Greater BMI, chronic kidney disease, recent exercise, and physical activity were modestly associated with elevated CK, while men ≥ 70 were less likely to have an elevated CK (Table). Race-ethnicity differences in CK remained after adjustment for BMI, waist circumference, and arm circumference. The 95th percentile of CK was 312 (95% CI 268 to 356) in white men, 712 (95% CI 530 to 894) in black men, 188 (95% CI 122 to 254) in white women, and 323 (95% CI 218 to 428) in black women (Figure).

Conclusion: Creatine kinase values in the general population are substantially higher in black patients particularly among men. These racial differences are not explained by differences in body composition. Proposed reference ranges for race-specific subgroups in this study are markedly higher than current reference ranges and provide a practical guide for clinicians when interpreting CK values.

Table: Multivariable logistic regression of odds of having creatine kinase above the upper limit of normal (334 IU/L in males, 199 IU/L in females)

Male

OR (95% CI) abnormal CK

Female

OR (95% CI) abnormal CK

Race-ethnicity (vs. White)

   Black

8.39 (6.11,11.52)***

5.08 (3.65,7.08)***

   Hispanic

1.72 (1.26,2.34)**

1.20 (0.83,1.73)

   Asian

2.41 (1.58,3.66)***

1.18 (0.68,2.03)

   Other

1.78 (0.82,3.85)

1.59 (0.65,3.87)

Age (vs. 20-29 years old)

   30-49

0.97 (0.70,1.34)

0.69 (0.41,1.15)

   50-69

0.52 (0.30,0.90)*

0.66 (0.36,1.23)

   ≥ 70

0.26 (0.11,0.60)**

0.55 (0.25,1.20)

BMI (vs. 20-25 kg/m2)

   < 18.5

0.55 (0.23,1.48)

0.20 (0.05,0.75)*

   25-30

2.29 (1.67,3.13)***

1.16 (0.75,1.79)

   ≥ 30

2.52 (1.80,3.54)***

1.11 (0.72,1.70)

GFR (vs. ≥ 90 ml/min/1.73m2)

   60-89

1.56 (1.22,1.99)**

1.60 (1.10,2.32)*

   30-59

2.21 (0.99,4.92)

2.06 (1.18,3.60)*

   <30

0.44 (0.07,2.88)

1.00 (0.30,3.34)

Exercise in past 3 days

1.78 (1.27,2.50)**

1.55 (0.89,2.68)

Vigorous recreation

1.49 (1.13,1.95)**

1.47 (0.97,2.23)

Heavy alcohol use, thyroid disease, hypertension, smoking, diabetes, cholesterol medication use, vigorous work included but not shown with p > 0.05 in men and women. BMI = body mass index. GFR = glomerular filtration rate. * < 0.05, ** < 0.01, *** < 0.001


Disclosure: N. K. McGill, None; J. F. Baker, None; M. D. George, None.

To cite this abstract in AMA style:

McGill NK, Baker JF, George MD. Creatine Kinase in the United States Population: Impact of Demographics, Comorbidities and Body Composition on the Normal Range [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/creatine-kinase-in-the-united-states-population-impact-of-demographics-comorbidities-and-body-composition-on-the-normal-range/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/creatine-kinase-in-the-united-states-population-impact-of-demographics-comorbidities-and-body-composition-on-the-normal-range/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology